Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRT and Aflibercept for Uveal Melanoma
NCT03712904Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2019
- Primary completion
- Sep 2022
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in Uveal melanoma (UM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Aug 2019; status: terminated.
02
Drugs
aflibercept
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT03712904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712904.